Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers

Phase 1 Completed 32 enrolled Novo Nordisk A/S

RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to determine the relative bioavailability of NNC 90-1170 (liraglutide) when inhaled compared to NNC 90-1170 when injected under the skin.

Timeline

Start: 2001-10
Primary completion: 2001-12
Completion: 2001-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Insulin	Protein / enzyme biologic	0.08 iu/kg	Other
Comparator	Insulin	Protein / enzyme biologic	0.4 iu/kg	Other
Subject	Liraglutide	Peptide	6 ug/kg	Other
Subject	Liraglutide	Peptide	12 ug/kg	Other
Subject	Liraglutide	Peptide	24 ug/kg	Other

Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers

Summary

Timeline

Drugs

Indications